Summary
Pulsenmore Ltd. reported that it has priced a private placement expected to raise approximately $7.5 million in gross proceeds. The financing announcement came as the company’s stock fell about 10% in reaction to the news. The offering was arranged with a healthcare-focused institutional investor and includes a mix of ordinary shares, pre-funded warrants and detachable warrants.
Deal structure and terms
Under a securities purchase agreement detailed in a press release, Pulsenmore agreed to sell 1,562,500 ordinary shares, or pre-funded warrants in lieu of those ordinary shares, together with ordinary warrants to purchase up to 1,562,500 ordinary shares. The combined purchase price for each ordinary share and its accompanying warrant is set at $4.80.
The ordinary warrants carry an exercise price of $4.80 per share, will be exercisable immediately upon issuance, and have a five-year term measured from the issuance date. The pre-funded warrants have an exercise price of $0.0001 per share and will be exercisable immediately until they are exercised in full.
Proceeds, timing and intended use
Pulsenmore expects the offering to generate gross proceeds of approximately $7.5 million, before deducting placement agent commissions and other estimated offering expenses. The company indicated that the closing of the offering is expected to occur on or about June 26, 2026, subject to the satisfaction of customary closing conditions.
Pulsenmore stated it plans to allocate the net proceeds for marketing and commercialization activities, working capital and other general corporate purposes. The company described the financing as supporting its next phase of growth and said it is intended to enable further expansion of its commercial footprint, particularly in the U.S. market.
Advisors
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
Key context and market reaction
The announcement of the private placement coincided with a roughly 10% decline in Pulsenmore’s share price. The offering’s structure includes both equity and warrant components, and the company noted that gross proceeds are before placement agent commissions and estimated offering expenses.
Key points
- Pulsenmore priced a private placement expected to raise about $7.5 million in gross proceeds through the sale of 1,562,500 ordinary shares (or pre-funded warrants) and 1,562,500 ordinary warrants.
- Ordinary warrants are exercisable immediately at $4.80 and expire five years after issuance; pre-funded warrants carry a $0.0001 exercise price and are exercisable until exercised in full.
- The company said net proceeds will be used for marketing and commercialization, working capital and general corporate purposes, with an emphasis on expanding its commercial footprint in the U.S.
Risks and uncertainties
- The offering’s closing is subject to customary closing conditions, creating uncertainty about whether and when the transaction will be completed - this affects capital markets participants and small-cap equity investors.
- Gross proceeds are stated before placement agent commissions and estimated offering expenses, meaning net proceeds available to the company will be lower than the $7.5 million gross figure - this is pertinent to Pulsenmore’s financial planning and commercialization spending.
- The market reacted negatively to the financing announcement, with the company’s shares falling about 10% - a factor relevant to investors in healthcare device equities and small-cap Nasdaq-listed firms.
Conclusion
Pulsenmore has structured a mixed equity and warrant financing intended to provide funding for commercialization and U.S. expansion. The company has stated its intended uses for the proceeds, set an expected closing near June 26, 2026, and named A.G.P./Alliance Global Partners as sole placement agent. The closing remains subject to customary conditions, and gross proceeds will be reduced by fees and offering expenses.